Loading...
•
Sep 30, 2024
Structure Therapeutics Q3 2024 Earnings Report
Structure Therapeutics reported its financial results for the third quarter ended September 30, 2024.
Key Takeaways
Structure Therapeutics reported a net loss of $34.0 million for the third quarter of 2024. The company's cash, cash equivalents, and short-term investments totaled $915.3 million as of September 30, 2024, which is expected to fund operations through at least 2027.
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity.
Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024.
Cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027.
R&D expenses for the third quarter of 2024 were $32.6 million.